PMID- 29054459
OWN - NLM
STAT- MEDLINE
DCOM- 20180813
LR  - 20180813
IS  - 1437-7780 (Electronic)
IS  - 1341-321X (Linking)
VI  - 24
IP  - 2
DP  - 2018 Feb
TI  - Lymphocyte subset analysis in QuantiFERON-TB Gold Plus and T-Spot.TB for latent 
      tuberculosis infection in rheumatoid arthritis.
PG  - 110-116
LID - S1341-321X(17)30231-3 [pii]
LID - 10.1016/j.jiac.2017.09.012 [doi]
AB  - Rheumatoid arthritis (RA) is an immune mediated inflammatory disorder, and immune 
      suppressive drugs are prescribed. RA patients receiving treatments are in a kind 
      of immunosuppressive condition that presents increased risk of developing active 
      tuberculosis. Accurate diagnosis of latent tuberculosis infection (LTBI) is 
      recommended for RA. QuantiFERON((R))-TB Gold Plus (QFT-Plus), a novel IGRA, has two 
      tubes (TB1 and TB2). TB2 is designed to elicit both CD4 and CD8 T-cell responses, 
      with expected increased sensitivity. We conducted a cross-sectional study to 
      compare two IGRAs, QFT-Plus and T-SPOT((R)).TB (TSPOT), in RA. One hundred 
      fifty-two RA patients (median age: 66.5 yrs) were enrolled. QFT-Plus and TSPOT 
      were concurrently conducted. Lymphocyte subsets (CD4 T-cell and CD8 T-cell) were 
      also measured. The positivity rates of QFT-Plus and TSPOT were 9.7% and 4.5%, 
      respectively, with the difference being significant (P < 0.01). The positivity 
      rates in TB1 and TB2 were 9.1% and 7.1%, respectively; the difference was not 
      significant (P = 0.18). Patients with CD4 T-cell >/=650/muL and CD8 T-cell >/=400/muL 
      had significantly higher positivity rates in both QFT-Plus and TSPOT in 
      comparison with other groups (P < 0.01 and P < 0.05, respectively). QFT-plus 
      demonstrated a higher positivity rate than TSPOT. However, there was little 
      additional effect for detecting LTBI by TB2. Lymphocyte subsets were strongly 
      associated with immune response in both QFT-Plus and TSPOT. LTBI should not be 
      ruled out even with a negative IGRA result in patients with CD4 T-cell <650/muL or 
      CD8 T-cell <400/muL.
CI  - Copyright (c) 2017 Japanese Society of Chemotherapy and The Japanese Association 
      for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
FAU - Igari, Hidetoshi
AU  - Igari H
AD  - Division of Infection Control, Chiba University Hospital, Chiba, Japan. 
      Electronic address: hide306@gmail.com.
FAU - Ishikawa, Satoru
AU  - Ishikawa S
AD  - Department of Respiratory Medicine, National Hospital Organization Chiba-East 
      Hospital, Chiba, Japan.
FAU - Nakazawa, Takuya
AU  - Nakazawa T
AD  - Center of Rheumatology, Allergy & Clinical Immunology, National Hospital 
      Organization Chiba-East Hospital, Chiba, Japan.
FAU - Oya, Yoshihiro
AU  - Oya Y
AD  - Center of Rheumatology, Allergy & Clinical Immunology, National Hospital 
      Organization Chiba-East Hospital, Chiba, Japan.
FAU - Futami, Hidekazu
AU  - Futami H
AD  - Center of Rheumatology, Allergy & Clinical Immunology, National Hospital 
      Organization Chiba-East Hospital, Chiba, Japan.
FAU - Tsuyuzaki, Mizue
AU  - Tsuyuzaki M
AD  - Chiba Foundation for Health Promotion and Disease Prevention, Chiba, Japan.
FAU - Suzuki, Kiminori
AU  - Suzuki K
AD  - Chiba Foundation for Health Promotion and Disease Prevention, Chiba, Japan.
FAU - Matsumura, Ryutaro
AU  - Matsumura R
AD  - Center of Rheumatology, Allergy & Clinical Immunology, National Hospital 
      Organization Chiba-East Hospital, Chiba, Japan.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20171018
PL  - Netherlands
TA  - J Infect Chemother
JT  - Journal of infection and chemotherapy : official journal of the Japan Society of 
      Chemotherapy
JID - 9608375
RN  - 0 (Antigens, Bacterial)
RN  - 0 (Immunosuppressive Agents)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antigens, Bacterial/immunology
MH  - Arthritis, Rheumatoid/complications/drug therapy/*immunology
MH  - CD4-Positive T-Lymphocytes/*immunology
MH  - CD8-Positive T-Lymphocytes/*immunology
MH  - Cell Count
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Immunosuppressive Agents/therapeutic use
MH  - *Interferon-gamma Release Tests
MH  - Latent Tuberculosis/complications/*diagnosis/*immunology
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Mycobacterium tuberculosis/immunology
MH  - T-Lymphocyte Subsets/*immunology
OTO - NOTNLM
OT  - Latent tuberculosis infection
OT  - Lymphocyte subsets
OT  - QuantiFERON-TB Gold Plus
OT  - Rheumatoid arthritis
OT  - T-SPOT.TB
EDAT- 2017/10/22 06:00
MHDA- 2018/08/14 06:00
CRDT- 2017/10/22 06:00
PHST- 2017/07/21 00:00 [received]
PHST- 2017/09/21 00:00 [revised]
PHST- 2017/09/25 00:00 [accepted]
PHST- 2017/10/22 06:00 [pubmed]
PHST- 2018/08/14 06:00 [medline]
PHST- 2017/10/22 06:00 [entrez]
AID - S1341-321X(17)30231-3 [pii]
AID - 10.1016/j.jiac.2017.09.012 [doi]
PST - ppublish
SO  - J Infect Chemother. 2018 Feb;24(2):110-116. doi: 10.1016/j.jiac.2017.09.012. Epub 
      2017 Oct 18.